Treatment of Mild Hypertension with Low Once-Daily Doses of a Sustained-Release Capsule Formulation of Verapamil
The efficacy and safety of a low dose (120 mg) of a sustained‐release capsule formulation of verapamil administered once daily in the treatment of 42 patients with mild hypertension were assessed in this clinical trial. After a 4‐week placebo washout period (baseline), patients with diastolic clinic...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pharmacology 1995-01, Vol.35 (1), p.52-58 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 58 |
|---|---|
| container_issue | 1 |
| container_start_page | 52 |
| container_title | Journal of clinical pharmacology |
| container_volume | 35 |
| creator | Davis, Pamela J. Fagan, Timothy C. Topmiller, Mary J. Levine, Jon H. Ferdinand, Keith C. |
| description | The efficacy and safety of a low dose (120 mg) of a sustained‐release capsule formulation of verapamil administered once daily in the treatment of 42 patients with mild hypertension were assessed in this clinical trial. After a 4‐week placebo washout period (baseline), patients with diastolic clinic blood pressures of 91 to 100 mm Hg inclusive were treated for 4 weeks with once‐daily verapamil sustained‐release 120 mg capsules. Clinic blood pressure was measured and 24‐hour ambulatory blood pressure monitoring was performed at the end of both the baseline and the 4‐week treatment periods. Twenty‐four hour, day, and night systolic and diastolic ambulatory blood pressures were significantly (P 85 mm Hg) and unconfirmed mild hypertension (≤85 mm Hg). The magnitude of the mean change in systolic and diastolic blood pressure was greater in the group of patients with confirmed mild hypertension than the group with unconfirmed hypertension. The incidence of adverse experiences was low in frequency and events were of mild severity; quality of life scores improved (P = 0.02). Low daily doses (120 mg) of verapamil sustained‐release capsules provide a well‐tolerated and sustained antihypertensive effect over 24 hours in patients with mild hypertension. |
| doi_str_mv | 10.1002/j.1552-4604.1995.tb04745.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77282134</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77282134</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4385-d53b96b20b471784c6f94eb2b7ae3e07f1fe765a8ce6315201040229957b26113</originalsourceid><addsrcrecordid>eNqVkF1v0zAUhi3ENLrBT0CyEOIuwZ9xwhWooytT9yE21kvLSU-Ei_OBnajtv1-iRr3f1bH0Puc91oPQJ0piSgj7uo2plCwSCRExzTIZdzkRSsh4_wbNTtFbNCMkoxFThLxDFyFsCaGJkPQcnSslqaB8htonD6aroO5wU-Jb6zZ4eWjBd1AH29R4Z7u_eNXs8H1dQHRlrDvgqyZAGHGDH_vQGVvDJvoNDkwAPDdt6B3gReOr3pluLBnQZ_CmNZV179FZaVyAD9O8RH8WP5_my2h1f_1r_mMVFYKnMtpInmdJzkguFFWpKJIyE5CzXBngQFRJS1CJNGkBCaeSEUoEYWyQoXKWUMov0Zdjb-ub_z2ETlc2FOCcqaHpg1aKpYxyMYDfjmDhmxA8lLr1tjL-oCnRo2691aNTPTrVo2496db7YfnjdKXPK9icVie_Q_55yk0ojCu9qQsbThgXJJFEDtj3I7azDg6v-IC-mT8sx-dQER0rbOhgf6ow_p9OFFdSr--udXrzsFg_rx91xl8ApyKruQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77282134</pqid></control><display><type>article</type><title>Treatment of Mild Hypertension with Low Once-Daily Doses of a Sustained-Release Capsule Formulation of Verapamil</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Davis, Pamela J. ; Fagan, Timothy C. ; Topmiller, Mary J. ; Levine, Jon H. ; Ferdinand, Keith C.</creator><creatorcontrib>Davis, Pamela J. ; Fagan, Timothy C. ; Topmiller, Mary J. ; Levine, Jon H. ; Ferdinand, Keith C.</creatorcontrib><description>The efficacy and safety of a low dose (120 mg) of a sustained‐release capsule formulation of verapamil administered once daily in the treatment of 42 patients with mild hypertension were assessed in this clinical trial. After a 4‐week placebo washout period (baseline), patients with diastolic clinic blood pressures of 91 to 100 mm Hg inclusive were treated for 4 weeks with once‐daily verapamil sustained‐release 120 mg capsules. Clinic blood pressure was measured and 24‐hour ambulatory blood pressure monitoring was performed at the end of both the baseline and the 4‐week treatment periods. Twenty‐four hour, day, and night systolic and diastolic ambulatory blood pressures were significantly (P <0.01) reduced in the entire study population (24‐hour, −5/−4 mm Hg; day, −6/−4 mm Hg; night, −4/–3 mm Hg). On the basis of mean daytime (6 AM to 6 PM) ambulatory diastolic blood pressure, patients were stratified into subgroups of patients with confirmed (>85 mm Hg) and unconfirmed mild hypertension (≤85 mm Hg). The magnitude of the mean change in systolic and diastolic blood pressure was greater in the group of patients with confirmed mild hypertension than the group with unconfirmed hypertension. The incidence of adverse experiences was low in frequency and events were of mild severity; quality of life scores improved (P = 0.02). Low daily doses (120 mg) of verapamil sustained‐release capsules provide a well‐tolerated and sustained antihypertensive effect over 24 hours in patients with mild hypertension.</description><identifier>ISSN: 0091-2700</identifier><identifier>EISSN: 1552-4604</identifier><identifier>DOI: 10.1002/j.1552-4604.1995.tb04745.x</identifier><identifier>PMID: 7751413</identifier><identifier>CODEN: JCPCBR</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Antihypertensive agents ; Biological and medical sciences ; Blood Pressure - drug effects ; Blood Pressure Monitoring, Ambulatory ; Capsules ; Cardiovascular system ; Chemistry, Pharmaceutical ; Delayed-Action Preparations ; Drug Administration Schedule ; Female ; Heart Rate - drug effects ; Humans ; Hypertension - drug therapy ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Quality of Life ; Single-Blind Method ; Surveys and Questionnaires ; Verapamil - administration & dosage ; Verapamil - therapeutic use</subject><ispartof>Journal of clinical pharmacology, 1995-01, Vol.35 (1), p.52-58</ispartof><rights>1995 American College of Clinical Pharmacology</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4385-d53b96b20b471784c6f94eb2b7ae3e07f1fe765a8ce6315201040229957b26113</citedby><cites>FETCH-LOGICAL-c4385-d53b96b20b471784c6f94eb2b7ae3e07f1fe765a8ce6315201040229957b26113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fj.1552-4604.1995.tb04745.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fj.1552-4604.1995.tb04745.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,4010,27900,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3406505$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7751413$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Davis, Pamela J.</creatorcontrib><creatorcontrib>Fagan, Timothy C.</creatorcontrib><creatorcontrib>Topmiller, Mary J.</creatorcontrib><creatorcontrib>Levine, Jon H.</creatorcontrib><creatorcontrib>Ferdinand, Keith C.</creatorcontrib><title>Treatment of Mild Hypertension with Low Once-Daily Doses of a Sustained-Release Capsule Formulation of Verapamil</title><title>Journal of clinical pharmacology</title><addtitle>J Clin Pharmacol</addtitle><description>The efficacy and safety of a low dose (120 mg) of a sustained‐release capsule formulation of verapamil administered once daily in the treatment of 42 patients with mild hypertension were assessed in this clinical trial. After a 4‐week placebo washout period (baseline), patients with diastolic clinic blood pressures of 91 to 100 mm Hg inclusive were treated for 4 weeks with once‐daily verapamil sustained‐release 120 mg capsules. Clinic blood pressure was measured and 24‐hour ambulatory blood pressure monitoring was performed at the end of both the baseline and the 4‐week treatment periods. Twenty‐four hour, day, and night systolic and diastolic ambulatory blood pressures were significantly (P <0.01) reduced in the entire study population (24‐hour, −5/−4 mm Hg; day, −6/−4 mm Hg; night, −4/–3 mm Hg). On the basis of mean daytime (6 AM to 6 PM) ambulatory diastolic blood pressure, patients were stratified into subgroups of patients with confirmed (>85 mm Hg) and unconfirmed mild hypertension (≤85 mm Hg). The magnitude of the mean change in systolic and diastolic blood pressure was greater in the group of patients with confirmed mild hypertension than the group with unconfirmed hypertension. The incidence of adverse experiences was low in frequency and events were of mild severity; quality of life scores improved (P = 0.02). Low daily doses (120 mg) of verapamil sustained‐release capsules provide a well‐tolerated and sustained antihypertensive effect over 24 hours in patients with mild hypertension.</description><subject>Adult</subject><subject>Aged</subject><subject>Antihypertensive agents</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Blood Pressure Monitoring, Ambulatory</subject><subject>Capsules</subject><subject>Cardiovascular system</subject><subject>Chemistry, Pharmaceutical</subject><subject>Delayed-Action Preparations</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Heart Rate - drug effects</subject><subject>Humans</subject><subject>Hypertension - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Quality of Life</subject><subject>Single-Blind Method</subject><subject>Surveys and Questionnaires</subject><subject>Verapamil - administration & dosage</subject><subject>Verapamil - therapeutic use</subject><issn>0091-2700</issn><issn>1552-4604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkF1v0zAUhi3ENLrBT0CyEOIuwZ9xwhWooytT9yE21kvLSU-Ei_OBnajtv1-iRr3f1bH0Puc91oPQJ0piSgj7uo2plCwSCRExzTIZdzkRSsh4_wbNTtFbNCMkoxFThLxDFyFsCaGJkPQcnSslqaB8htonD6aroO5wU-Jb6zZ4eWjBd1AH29R4Z7u_eNXs8H1dQHRlrDvgqyZAGHGDH_vQGVvDJvoNDkwAPDdt6B3gReOr3pluLBnQZ_CmNZV179FZaVyAD9O8RH8WP5_my2h1f_1r_mMVFYKnMtpInmdJzkguFFWpKJIyE5CzXBngQFRJS1CJNGkBCaeSEUoEYWyQoXKWUMov0Zdjb-ub_z2ETlc2FOCcqaHpg1aKpYxyMYDfjmDhmxA8lLr1tjL-oCnRo2691aNTPTrVo2496db7YfnjdKXPK9icVie_Q_55yk0ojCu9qQsbThgXJJFEDtj3I7azDg6v-IC-mT8sx-dQER0rbOhgf6ow_p9OFFdSr--udXrzsFg_rx91xl8ApyKruQ</recordid><startdate>199501</startdate><enddate>199501</enddate><creator>Davis, Pamela J.</creator><creator>Fagan, Timothy C.</creator><creator>Topmiller, Mary J.</creator><creator>Levine, Jon H.</creator><creator>Ferdinand, Keith C.</creator><general>Blackwell Publishing Ltd</general><general>Sage Science</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199501</creationdate><title>Treatment of Mild Hypertension with Low Once-Daily Doses of a Sustained-Release Capsule Formulation of Verapamil</title><author>Davis, Pamela J. ; Fagan, Timothy C. ; Topmiller, Mary J. ; Levine, Jon H. ; Ferdinand, Keith C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4385-d53b96b20b471784c6f94eb2b7ae3e07f1fe765a8ce6315201040229957b26113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antihypertensive agents</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Blood Pressure Monitoring, Ambulatory</topic><topic>Capsules</topic><topic>Cardiovascular system</topic><topic>Chemistry, Pharmaceutical</topic><topic>Delayed-Action Preparations</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Heart Rate - drug effects</topic><topic>Humans</topic><topic>Hypertension - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Quality of Life</topic><topic>Single-Blind Method</topic><topic>Surveys and Questionnaires</topic><topic>Verapamil - administration & dosage</topic><topic>Verapamil - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Davis, Pamela J.</creatorcontrib><creatorcontrib>Fagan, Timothy C.</creatorcontrib><creatorcontrib>Topmiller, Mary J.</creatorcontrib><creatorcontrib>Levine, Jon H.</creatorcontrib><creatorcontrib>Ferdinand, Keith C.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Davis, Pamela J.</au><au>Fagan, Timothy C.</au><au>Topmiller, Mary J.</au><au>Levine, Jon H.</au><au>Ferdinand, Keith C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Mild Hypertension with Low Once-Daily Doses of a Sustained-Release Capsule Formulation of Verapamil</atitle><jtitle>Journal of clinical pharmacology</jtitle><addtitle>J Clin Pharmacol</addtitle><date>1995-01</date><risdate>1995</risdate><volume>35</volume><issue>1</issue><spage>52</spage><epage>58</epage><pages>52-58</pages><issn>0091-2700</issn><eissn>1552-4604</eissn><coden>JCPCBR</coden><abstract>The efficacy and safety of a low dose (120 mg) of a sustained‐release capsule formulation of verapamil administered once daily in the treatment of 42 patients with mild hypertension were assessed in this clinical trial. After a 4‐week placebo washout period (baseline), patients with diastolic clinic blood pressures of 91 to 100 mm Hg inclusive were treated for 4 weeks with once‐daily verapamil sustained‐release 120 mg capsules. Clinic blood pressure was measured and 24‐hour ambulatory blood pressure monitoring was performed at the end of both the baseline and the 4‐week treatment periods. Twenty‐four hour, day, and night systolic and diastolic ambulatory blood pressures were significantly (P <0.01) reduced in the entire study population (24‐hour, −5/−4 mm Hg; day, −6/−4 mm Hg; night, −4/–3 mm Hg). On the basis of mean daytime (6 AM to 6 PM) ambulatory diastolic blood pressure, patients were stratified into subgroups of patients with confirmed (>85 mm Hg) and unconfirmed mild hypertension (≤85 mm Hg). The magnitude of the mean change in systolic and diastolic blood pressure was greater in the group of patients with confirmed mild hypertension than the group with unconfirmed hypertension. The incidence of adverse experiences was low in frequency and events were of mild severity; quality of life scores improved (P = 0.02). Low daily doses (120 mg) of verapamil sustained‐release capsules provide a well‐tolerated and sustained antihypertensive effect over 24 hours in patients with mild hypertension.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>7751413</pmid><doi>10.1002/j.1552-4604.1995.tb04745.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-2700 |
| ispartof | Journal of clinical pharmacology, 1995-01, Vol.35 (1), p.52-58 |
| issn | 0091-2700 1552-4604 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77282134 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Antihypertensive agents Biological and medical sciences Blood Pressure - drug effects Blood Pressure Monitoring, Ambulatory Capsules Cardiovascular system Chemistry, Pharmaceutical Delayed-Action Preparations Drug Administration Schedule Female Heart Rate - drug effects Humans Hypertension - drug therapy Male Medical sciences Middle Aged Pharmacology. Drug treatments Quality of Life Single-Blind Method Surveys and Questionnaires Verapamil - administration & dosage Verapamil - therapeutic use |
| title | Treatment of Mild Hypertension with Low Once-Daily Doses of a Sustained-Release Capsule Formulation of Verapamil |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T15%3A06%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Mild%20Hypertension%20with%20Low%20Once-Daily%20Doses%20of%20a%20Sustained-Release%20Capsule%20Formulation%20of%20Verapamil&rft.jtitle=Journal%20of%20clinical%20pharmacology&rft.au=Davis,%20Pamela%20J.&rft.date=1995-01&rft.volume=35&rft.issue=1&rft.spage=52&rft.epage=58&rft.pages=52-58&rft.issn=0091-2700&rft.eissn=1552-4604&rft.coden=JCPCBR&rft_id=info:doi/10.1002/j.1552-4604.1995.tb04745.x&rft_dat=%3Cproquest_cross%3E77282134%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77282134&rft_id=info:pmid/7751413&rfr_iscdi=true |